- Email: [email protected]
4762711 Live vaccine for bovine babesiosis
New Patents
A novel 1,2-dithiol-3-thione derivative which has an immunomodulating property, which is expressed by the formula (I): See Patent for Chemical Structure (I) wherein R denotes hydrogen, halogen, lower alkoxy group, lower alkyl group, amino group, lower alkyl-substituted amino group or lower alkoxycarbonyl group.
4761283 IMMUNOGENIC
CONJUGATES
Porter W Anderson assigned to The University of Rochester An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
4761470 IMMUNOGENIC SYNTHETIC PEPTIDE CAPABLE OF ELICITING HERPES SIMPLEX VIRUS NEUTRALIZING ANTIBODY Emilio Emini, Vivian M Larson, Joshua S Boger assigned to Merck & Co Inc A synthetic peptide, containing the predicted amino acid residues 64 to 77 of the herpes simplex virus type 1 (HSVI) gB structural glycoprotein open reading frame, a synthetic subunit immunogen that stimulates an immune response against HSVI and which, when prepared, and chemically-conjugated to a protein carrier molecule, and inoculated into test animals, gives rise to a specific anti-peptide IgG response, such that these anti-peptide antibodies react with a purified HSV-specific structural glycoprotein preparation and are capable of neutralizing the infectivity of HSVI.
4761490 ORGANIC DERIVATIVES OF TELLURIUM AND SELENIUM AND THEIR USE TO STIMULATE CYTOKINE PRODUCTION Michael Albeck, Benjamin Sredni, Ramat Gan, Israel assigned to Bar-llan University
4761370 METHOD FOR DETERMINING THE PRESENCE OF BACTERIA IN BODY FLUID SPECIMENS CONTAINING BACTERIAL INHIBITORS Michael J Caulfield, Shaker Hts, OH, United Statee assigned to Cleveland Clinic Foundation A method for determining the presence of bacteria in a body fluid specimen containing bacterial inhibitors is provided wherein a body fluid specimen containing bacterial inhibitors is procured, and growth media for the bacteria and antibodies specific to the bacterial inhibitors are added to neutralize the effectiveness of the bacterial inhibitors, and after incubation of the reactive mixture the presence of bacteria in the body fluid specimen is determined. An apparatus for accomplishing the foregoing is also provided.
Certain tellurium compounds have been found to have the ability to stimulate the in vivo and in vitro production of cytokines and their receptors. These compounds may be utilized in the treatment of certain tumors, autoimmune diseases, immune diseases and infectious diseases.
4762711 LIVE VACCINE FOR BOVINE BABESIOSIS Gerald Buening, Charles Carson assigned to The Curators of the University of Missouri A live vaccine for bovine babesiosis comprises viable bovine erythrocytes parasitized with a cloned population of Babesia bovis, the clone strain being fast-growing, avirulent, and producing a mild but immunizing infection when administered. The vaccine is free of slow-
New Patents
vii
growing virulent B. bovis, The clone strain used in the vaccine is prepared from a natural mixture of virulent and avirulent babesia by progressive dilution culturing to obtain cultures containing single parasites, propagating the single parasites under favorable conditions for growth, and selecting a fast-growing avirulent clone line for either in vitro or in vivo propagation to prepare the vaccines.
infants caused by bacterial pathogens, by administering an effective amount of the abovedescribed conjugate, followed by the capsular polymer fragments alone.
4762712
Gautam Mitra, Milton M Mozen assigned to Miles Laboratories Inc
ANTI-MASTITIS POLYVALENT VACCINE, METHOD OF ADMINISTRATION AND METHOD FOR PRODUCTION THEREOF Ralph J Stolle, Lee Beck assigned to Stolle Research & Development Corporation A process for the production of a polyvalent vaccine effective in the prevention and treatment of mastitis in bovine animals is disclosed, which comprises periodically culturing the milk of animals exhibiting preclinical mastitis to cultivate any pathogens present therein, killing those pathogens and incorporating each strain of cultivated, killed pathogen in a pharmacological carrier together with all other strains previously identified. The process is repeated to ensure all newly appearing pathogenic strains are vaccinated against. The vaccine so produced has been demonstated to be effective in reversal of hard udder syndrome. 4762713 BOOSTING OF IMMUNOGENIC C O N J U G A T E V A C C I N A T I O N S BY UNCONJUGATED BACTERIAL CAPSULAR POLYMERS Porter Anderson assigned to The University of Rochester This invention relates to immunogenic conjugates of capsular polymers or polymer fragments from bacterial pathogens and bacterial toxins, toxoids or subunits. The invention also relates to methods for the preparation of the conjugates and a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in human infants. Also disclosed are methods for inducing active immunization against systemic infection in human
4762714 PREPARATION OF RETROVIRUSFREE IMMUNOGLOBULINS
Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by preparing the ISG from human plasma using a cold ethanol plasma fractionation process at a pH equal to or less than 5.4 and then storing the ISG at either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27 degrees C. for at least 3 days, or (2) at a pH equal to or less th
4762848 1,3-THIAZOLES AND THEIR USE AS IMMUNOMODULATORS Karl-Heinz Scheunemann, Walter Durckheimer, Jurgen Blumbach, Michael Limbert, Hans-Ulrich Schorlemmer, Gerhard Dickneite, Hans-Harald Sedlacek, Frankfurt am Main, Federal Republic Of Germany assigned to Hoechst Aktiengesellschaft Heterocyclic sulfides of the general formula heterocycle-S-R, a process for their preparation and, in particular, their use for immunostimulation, immunorestoration and cytostatic treatment, and pharmaceutical agents, which contain a sulfide of this type, for these indications.
4764370 VACCINE UTILIZING AN AVIRULENT STRAIN OF SALMONELLA TYPHIMURIUM Patricia Fields, Constantine G Haidaris, Frederick L Heffron assigned to Scripps Clinic and Research Foundation A vaccine against a microbial pathogen comprised of a live, immunogenic but prototrophic and avirulent mutant strain of the selected
A novel 1,2-dithiol-3-thione derivative which has an immunomodulating property, which is expressed by the formula (I): See Patent for Chemical Structure (I) wherein R denotes hydrogen, halogen, lower alkoxy group, lower alkyl group, amino group, lower alkyl-substituted amino group or lower alkoxycarbonyl group.
4761283 IMMUNOGENIC
CONJUGATES
Porter W Anderson assigned to The University of Rochester An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
4761470 IMMUNOGENIC SYNTHETIC PEPTIDE CAPABLE OF ELICITING HERPES SIMPLEX VIRUS NEUTRALIZING ANTIBODY Emilio Emini, Vivian M Larson, Joshua S Boger assigned to Merck & Co Inc A synthetic peptide, containing the predicted amino acid residues 64 to 77 of the herpes simplex virus type 1 (HSVI) gB structural glycoprotein open reading frame, a synthetic subunit immunogen that stimulates an immune response against HSVI and which, when prepared, and chemically-conjugated to a protein carrier molecule, and inoculated into test animals, gives rise to a specific anti-peptide IgG response, such that these anti-peptide antibodies react with a purified HSV-specific structural glycoprotein preparation and are capable of neutralizing the infectivity of HSVI.
4761490 ORGANIC DERIVATIVES OF TELLURIUM AND SELENIUM AND THEIR USE TO STIMULATE CYTOKINE PRODUCTION Michael Albeck, Benjamin Sredni, Ramat Gan, Israel assigned to Bar-llan University
4761370 METHOD FOR DETERMINING THE PRESENCE OF BACTERIA IN BODY FLUID SPECIMENS CONTAINING BACTERIAL INHIBITORS Michael J Caulfield, Shaker Hts, OH, United Statee assigned to Cleveland Clinic Foundation A method for determining the presence of bacteria in a body fluid specimen containing bacterial inhibitors is provided wherein a body fluid specimen containing bacterial inhibitors is procured, and growth media for the bacteria and antibodies specific to the bacterial inhibitors are added to neutralize the effectiveness of the bacterial inhibitors, and after incubation of the reactive mixture the presence of bacteria in the body fluid specimen is determined. An apparatus for accomplishing the foregoing is also provided.
Certain tellurium compounds have been found to have the ability to stimulate the in vivo and in vitro production of cytokines and their receptors. These compounds may be utilized in the treatment of certain tumors, autoimmune diseases, immune diseases and infectious diseases.
4762711 LIVE VACCINE FOR BOVINE BABESIOSIS Gerald Buening, Charles Carson assigned to The Curators of the University of Missouri A live vaccine for bovine babesiosis comprises viable bovine erythrocytes parasitized with a cloned population of Babesia bovis, the clone strain being fast-growing, avirulent, and producing a mild but immunizing infection when administered. The vaccine is free of slow-
New Patents
vii
growing virulent B. bovis, The clone strain used in the vaccine is prepared from a natural mixture of virulent and avirulent babesia by progressive dilution culturing to obtain cultures containing single parasites, propagating the single parasites under favorable conditions for growth, and selecting a fast-growing avirulent clone line for either in vitro or in vivo propagation to prepare the vaccines.
infants caused by bacterial pathogens, by administering an effective amount of the abovedescribed conjugate, followed by the capsular polymer fragments alone.
4762712
Gautam Mitra, Milton M Mozen assigned to Miles Laboratories Inc
ANTI-MASTITIS POLYVALENT VACCINE, METHOD OF ADMINISTRATION AND METHOD FOR PRODUCTION THEREOF Ralph J Stolle, Lee Beck assigned to Stolle Research & Development Corporation A process for the production of a polyvalent vaccine effective in the prevention and treatment of mastitis in bovine animals is disclosed, which comprises periodically culturing the milk of animals exhibiting preclinical mastitis to cultivate any pathogens present therein, killing those pathogens and incorporating each strain of cultivated, killed pathogen in a pharmacological carrier together with all other strains previously identified. The process is repeated to ensure all newly appearing pathogenic strains are vaccinated against. The vaccine so produced has been demonstated to be effective in reversal of hard udder syndrome. 4762713 BOOSTING OF IMMUNOGENIC C O N J U G A T E V A C C I N A T I O N S BY UNCONJUGATED BACTERIAL CAPSULAR POLYMERS Porter Anderson assigned to The University of Rochester This invention relates to immunogenic conjugates of capsular polymers or polymer fragments from bacterial pathogens and bacterial toxins, toxoids or subunits. The invention also relates to methods for the preparation of the conjugates and a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in human infants. Also disclosed are methods for inducing active immunization against systemic infection in human
4762714 PREPARATION OF RETROVIRUSFREE IMMUNOGLOBULINS
Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by preparing the ISG from human plasma using a cold ethanol plasma fractionation process at a pH equal to or less than 5.4 and then storing the ISG at either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27 degrees C. for at least 3 days, or (2) at a pH equal to or less th
4762848 1,3-THIAZOLES AND THEIR USE AS IMMUNOMODULATORS Karl-Heinz Scheunemann, Walter Durckheimer, Jurgen Blumbach, Michael Limbert, Hans-Ulrich Schorlemmer, Gerhard Dickneite, Hans-Harald Sedlacek, Frankfurt am Main, Federal Republic Of Germany assigned to Hoechst Aktiengesellschaft Heterocyclic sulfides of the general formula heterocycle-S-R, a process for their preparation and, in particular, their use for immunostimulation, immunorestoration and cytostatic treatment, and pharmaceutical agents, which contain a sulfide of this type, for these indications.
4764370 VACCINE UTILIZING AN AVIRULENT STRAIN OF SALMONELLA TYPHIMURIUM Patricia Fields, Constantine G Haidaris, Frederick L Heffron assigned to Scripps Clinic and Research Foundation A vaccine against a microbial pathogen comprised of a live, immunogenic but prototrophic and avirulent mutant strain of the selected